About UTILITY therapeutics
UTILITY therapeutics is a company based in Altrincham (United Kingdom) founded in 2017 by Peter Villadsen and Rasmus Kehler was acquired by Alembic Pharmaceuticals in July 2025. UTILITY therapeutics has raised $2.52 million across 2 funding rounds from investors including Alembic Pharmaceuticals. The company has 7 employees as of December 31, 2023. UTILITY therapeutics offers products and services including Antibiotic Therapies and Product Pipeline. UTILITY therapeutics operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter Altrincham, United Kingdom
- Employees 7 as on 31 Dec, 2023
- Founders Peter Villadsen, Rasmus Kehler
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Utility Therapeutics Ltd
- Date of Incorporation 19 Dec, 2017
- Jurisdiction ALTRINCHAM, CHESHIRE, UNITED KINGDOM
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.52 M (USD)
in 2 rounds
-
Latest Funding Round
$2.5 M (USD), Seed
Jul 08, 2019
- Investors
-
Employee Count
7
as on Dec 31, 2023
-
Acquired by
Alembic Pharmaceuticals
(Jul 03, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of UTILITY therapeutics
UTILITY therapeutics offers a comprehensive portfolio of products and services, including Antibiotic Therapies and Product Pipeline.
Develops drugs to combat drug-resistant urinary tract infections
Advances novel treatments for UTIs and related infections
People of UTILITY therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of UTILITY therapeutics
UTILITY therapeutics has successfully raised a total of $2.52M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $2.5 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in UTILITY therapeutics
UTILITY therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Alembic Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Manufacturer & supplier of generic pharmaceuticals
|
Locked | Locked | Locked |
Investor details for UTILITY therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by UTILITY therapeutics
Investment portfolio details for UTILITY therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - UTILITY therapeutics
Detailed financials for UTILITY therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Utility Therapeutics Comparisons
Peer comparison for UTILITY therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of UTILITY therapeutics
UTILITY therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| Locked | Locked | Locked |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| Locked | Locked | Locked |
Developer of antibiotics for MDR infections
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| Locked | Locked | Locked |
Therapeutics for antimicrobial resistant infections are developed.
|
Detailed competitors of UTILITY therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Utility Therapeutics
Complete news archive for UTILITY therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about UTILITY therapeutics
UTILITY therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
UTILITY therapeutics is headquartered in Altrincham, United Kingdom. It is registered at Altrincham, Greater Manchester, United Kingdom.
Thomas Hadley is the current CEO of UTILITY therapeutics.
UTILITY therapeutics is a funded company, having raised a total of $2.52M across 2 funding rounds to date.
As of Dec 31, 2023, the latest employee count at UTILITY therapeutics is 7.
Developer of antibiotics to treat urinary tract infections and multi-drug resistant infections. It offers Pivmecillinam is an aminopenicillin, which is a specific class of beta-lactam antibiotic and mecillinam (a member of the penicillin subgroup of the β-lactam antibiotic class), is an oral prodrug pivmecillinam for the treatment of urinary tract infections.
UTILITY therapeutics's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
UTILITY therapeutics offers Antibiotic Therapies and Product Pipeline.
UTILITY therapeutics has 1 investor. Key investors include Alembic Pharmaceuticals.